This document presents a coherent, yet non-prescriptive framework for tuning COVID-19 response measures in the European Union and European Economic Area (EU/EEA). Its aim is to ensure efficiency and encourage public trust and compliance, while continuing to protect the health of European citizens.
This document outlines the public health considerations for the use of self-tests to detect SARS-CoV-2 by public health authorities in the European Union/European Economic Area (EU/EEA). Only rapid antigen detection tests (RADTs) for self-testing for direct detection of SARS-CoV-2 virus particles in infectious individuals are considered within this document.
This document provides guidance based on scientific evidence regarding quarantine and testing of travellers in EU/EEA countries in the context of the emergence of SARS-CoV-2 variants of concern (VOCs).
This document aims to provide guidance to EU/EEA healthcare facilities and healthcare providers on infection prevention and control (IPC) measures for the management of suspected and confirmed cases of COVID-19 infection in healthcare settings, including long-term care facilities. It also offers guidance on the management of specimens at laboratories in the EU/EEA.
This technical guidance aims to provide guidelines to laboratories and relevant stakeholders in the European Union (EU), European Economic Area (EEA) and other countries in the WHO European region in making decisions on establishing sequencing capacities and capabilities, in making decisions on which technologies to use and/or in deciding on the role of sequencing for SARS-CoV-2 diagnostics, research, outbreak investigations and surveillance.
This document builds on a previously published ECDC report, ‘Key aspects regarding the introduction and prioritisation of COVID-19 vaccination in the EU/EEA and the UK’ [15]. By using mathematical modelling, this document provides EU/EEA countries with information on factors that may affect the choice of COVID-19 vaccination
This joint ECDC-European Union Aviation Safety Agency (EASA) document aims to support Member States in determining a coordinated approach to reduce the risks related to the movement of people by air within and between the EU/EEA countries and the UK in the context of the COVID-19 pandemic and current advice on avoiding non-essential travel.
Urgent action is required to improve efforts to prevent hepatitis B and C infections in the EU/EEA and the UK if the region is to meet the 2020 targets for the elimination of viral hepatitis as a serious threat to public health. Significant gaps in the reported data in relation to prevalence and prevention of HBV and HCV in EU/EEA and the UK present a major challenge to monitoring progress towards the targets for elimination of hepatitis.
In May 2020, ECDC produced a set of short-term forecasts of the expected number of COVID-19 cases, deaths and hospitalised cases (subdivided into general hospital wards and intensive care units). Updated forecasts were published in September 2020. In this report we present slightly longer-term projections for each country, up until 25 December 2020.